2-(4-Tert-butylphenyl)-5-methylsulfanyl-1,3,4-oxadiazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Tert-butylphenyl)-5-methylsulfanyl-1,3,4-oxadiazole
• 化学式: C₁₃H₁₆N₂OS
• 分子量: 248.35
• InChiKey: IUXDTVSAPLZNHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PRODRUGS COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST LINKER HYALURONIC ACID CONJUGATE
  申请人：SANOFI

  公开号：EP3302567B1

  公开（公告）日：2019-09-11
• [EN] CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID<br/>[FR] CONJUGUÉS COMPRENANT UN AGONISTE DOUBLE DE GLP-1/GLUCAGON, UN LIEUR ET DE L'ACIDE HYALURONIQUE
  申请人：SANOFI SA

  公开号：WO2018100174A1

  公开（公告）日：2018-06-07

  The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing - L1 −L2 - L - Y - R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety - by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.